XVIVO — Xvivo Perfusion AB Share News
0.000.00%
- SEK6.49bn
- SEK6.30bn
- SEK812.17m
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength
Brief: Xvivo Q2 EBIT SEK 25 Million
Sweden's XVIVO Q1 net sales growth tops expectations, swings to profit
Brief: Xvivo Q1 EBIT SEK 31.9 Million
Brief: Xvivo Perfusion CFO To Change
Sweden's Xvivo beats Q4 sales expectations, posts 10% organic growth
Brief: XVIVO Q4 Net Income At SEK 31.6 Million
Brief: Xvivo Q3 EBIT SEK 17.9 Million
Brief: CE Approval For Xvivo's Perfusion Solution For Heart Preservation Is Delayed
Brief: Xvivo Q2 EBIT SEK 7.1 Million
Brief: Xvivo Q1 EBIT SEK 26.6 Million
Brief: Xvivo Q4 EBIT SEK 15.5 Million
Brief: Xvivo Perfusion Says Evlp Business Driving Force In Q3
Brief: Xvivo Q3 EBIT SEK 20.5 Million
Brief: Xvivo Acquires Communication Platform For Transplant Process
Brief: Xvivo Q2 EBIT SEK 33.4 Million